Skip to main content
Canna~Fangled Abstracts

Cys-loop receptors on cannabinoids: All high?

By November 9, 2022November 29th, 2022No Comments

. 2022 Nov 9;13:1044575.

doi: 10.3389/fphys.2022.1044575. eCollection 2022.

Philip Schmiedhofer 1, Florian Daniel Vogel 2, Filip Koniuszewski 2, Margot Ernst 2
Affiliations 

Abstract

Endocannabinoids (eCBS) are endogenously derived lipid signaling molecules that serve as tissue hormones and interact with multiple targets, mostly within the endocannabinoid system (ECS). The ECS is a highly conserved regulatory system involved in homeostatic regulation, organ formation, and immunomodulation of chordates. The term “cannabinoid” evolved from the distinctive class of plant compounds found in Cannabis sativa, an ancient herb, due to their action on CB1 and CB2 receptors. CB1/2 receptors are the primary targets for eCBs, but their effects are not limited to the ECS. Due to the high interest and extensive research on the ECS, knowledge on its constituents and physiological role is substantial and still growing. Crosstalk and multiple targeting of molecules are common features of endogenous and plant compounds. Cannabimimetic molecules can be divided according to their origin, natural or synthetic, including phytocannabinoids (pCB’s) or synthetic cannabinoids (sCB’s). The endocannabinoid system (ECS) consists of receptors, transporters, enzymes, and signaling molecules. In this review, we focus on the effects of cannabinoids on Cys-loop receptors. Cys-loop receptors belong to the class of membrane-bound pentameric ligand gated ion channels, each family comprising multiple subunits. Mammalians possess GABA type A receptors (GABAAR), glycine receptors (GlyR), serotonin receptors type 3 (5-HT3R), and nicotinic acetylcholine receptors (nAChR). Several studies have shown different modulatory effects of CBs on multiple members of the Cys-loop receptor family. We highlight the existing knowledge, especially on subunits and protein domains with conserved binding sites for CBs and their possible pharmacological and physiological role in epilepsy and in chronic pain. We further discuss the potential for cannabinoids as first line treatments in epilepsy, chronic pain and other neuropsychiatric conditions, indicated by their polypharmacology and therapeutic profile.

Keywords: Cys-loop receptors, cannabinoid, cbd, chronic pain, epilepsy, polypharmacology, polypharmacy, thc

Figures

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

References

    1. Abrams D. I., Couey P., Shade S. B., Kelly M. E., Benowitz N. L. (2011). Cannabinoid-opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90, 844–851. 10.1038/clpt.2011.188 – DOI – PubMed
    1. Absalom N. L., Liao V. W. Y., Johannesen K. M. H., Gardella E., Jacobs J., Lesca G., et al. (2022). Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nat. Commun. 13, 1822. 10.1038/s41467-022-29280-x – DOI – PMC – PubMed
    1. Afrazi S., Esmaeili-Mahani S. (2014). Allopregnanolone suppresses diabetes-induced neuropathic pain and motor deficit through inhibition of GABAA receptor down-regulation in the spinal cord of diabetic rats. Iran. J. Basic Med. Sci. 17, 312–317. – PMC – PubMed
    1. Ahring P. K., Liao V. W. Y., Gardella E., Johannesen K. M., Krey I., Selmer K. K., et al. (2022a). Gain-of-function variants in GABRD reveal a novel pathway for neurodevelopmental disorders and epilepsy. Brain. 145, 1299–1309. 10.1093/brain/awab391 – DOI – PMC – PubMed
    1. Ahring P. K., Liao V. W. Y., Lin S., Absalom N. L., Chebib M., Møller R. S. (2022b). The de novo GABRA4 p.Thr300Ile variant found in a patient with early-onset intractable epilepsy and neurodevelopmental abnormalities displays gain-of-function traits. Epilepsia 63, 2439–2441. epi.17358. 10.1111/epi.17358 – DOI – PubMed

Publication types

Leave a Reply